Zacks: Analysts Expect VBI Vaccines Inc. (NASDAQ:VBIV) Will Announce Earnings of -$0.08 Per Share

Equities research analysts expect that VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) will announce earnings per share (EPS) of ($0.08) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for VBI Vaccines’ earnings. VBI Vaccines posted earnings of ($0.07) per share during the same quarter last year, which suggests a negative year over year growth rate of 14.3%. The firm is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that VBI Vaccines will report full year earnings of ($0.31) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.29). For the next financial year, analysts expect that the business will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.29) to ($0.16). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV – Get Rating) last issued its earnings results on Monday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.14 million. VBI Vaccines had a negative net margin of 11,054.36% and a negative return on equity of 42.79%.

A number of research firms have recently weighed in on VBIV. Jefferies Financial Group assumed coverage on VBI Vaccines in a research report on Thursday, December 30th. They set a “buy” rating and a $6.00 target price for the company. Raymond James cut their target price on VBI Vaccines from $9.00 to $6.00 and set a “strong-buy” rating on the stock in a report on Tuesday, March 8th. Finally, Zacks Investment Research raised VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Tuesday, April 5th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Balyasny Asset Management LLC acquired a new position in VBI Vaccines in the third quarter valued at $2,718,000. Goldman Sachs Group Inc. raised its position in shares of VBI Vaccines by 243.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,153,567 shares of the biopharmaceutical company’s stock worth $2,699,000 after acquiring an additional 818,173 shares in the last quarter. Millennium Management LLC lifted its stake in shares of VBI Vaccines by 44.5% in the 4th quarter. Millennium Management LLC now owns 1,741,498 shares of the biopharmaceutical company’s stock valued at $4,075,000 after purchasing an additional 535,968 shares during the period. BlackRock Inc. boosted its position in shares of VBI Vaccines by 3.6% during the 4th quarter. BlackRock Inc. now owns 13,269,221 shares of the biopharmaceutical company’s stock valued at $31,049,000 after purchasing an additional 462,785 shares in the last quarter. Finally, UBS Group AG grew its stake in VBI Vaccines by 703.1% during the third quarter. UBS Group AG now owns 460,199 shares of the biopharmaceutical company’s stock worth $1,431,000 after purchasing an additional 402,895 shares during the period. 43.61% of the stock is owned by institutional investors and hedge funds.

NASDAQ:VBIV traded down $0.05 during trading hours on Monday, reaching $1.65. 1,699,773 shares of the company were exchanged, compared to its average volume of 2,326,024. The business has a 50 day moving average of $1.54 and a 200 day moving average of $2.23. VBI Vaccines has a 1-year low of $1.21 and a 1-year high of $4.31. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.00 and a quick ratio of 3.92. The company has a market capitalization of $424.55 million, a P/E ratio of -6.11 and a beta of 1.97.

VBI Vaccines Company Profile (Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Featured Stories